NOXXON Pharma NV (ALNOX.PA) WACC Analysis

As of May 22, 2025, NOXXON Pharma NV (ALNOX.PA) carries a Weighted Average Cost of Capital (WACC) of 8.8%. WACC reflects the blended rate NOXXON Pharma NV must pay to both equity and debt holders.

Within that, the cost of equity is 7.3%, the cost of debt is 5.0%, and the effective tax rate is 29.8%.

Breakdown of WACC Components

• Long-term bond rate: 2.6% – 3.1%
• Equity market risk premium: 5.2% – 6.2%
• Adjusted beta: 0.9 – 1.08
• Additional risk adjustment: 0.0% – 0.5%
• Debt-to-equity ratio: 0

What It Means for Investors

With a selected WACC of 8.8%, NOXXON Pharma NV must ensure any new investment returns exceed this threshold to generate shareholder value. This level reflects a moderate financing cost structure.